Opthea to present at upcoming events to highlight work on wet AMD

(Image credit: AdobeStock/Plaifah)

The wet AMD work that Opthea is conducting will be highlighted at 2 upcoming events: The Congress of the Asia-Pacific Vitreo-Retina Society (APVRS) and the Ophthalmology Innovation Summit XIV (OIS).¹

The 17th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS)

• Presentation: Intravitreal Sozinibercept (anti-VEGF-C/-D ‘trap’) Combined with Ranibizumab for the Treatment of Polypoidal Choroidal Vasculopathy: A Predefined Phase 2b Subgroup Analysis
• Presenter: Gregg T. Kokame, MD, MMM, FASRS
• Date/Time: Friday, November 22, 2024, 3:15 – 3:20 PM Singapore time (GMT+8)

During this presentation, Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.¹

Abstract available online: https://2024.apvrs.org/abstract/?code=200963

Ophthalmology Innovation Summit XIV (OIS)

• Session: Retina Innovation Showcase
• Presenter: Frederic Guerard, PharmD, CEO, Opthea
• Date/Time: Saturday, November 23, 2024, 11:15 AM – 12:50 PM PT

The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. This event will be held in San Diego, California from November 22-23, 2024.²

Reference:

1. Opthea’s Wet AMD Program Featured at Ophthalmology Events. Opthea Limited. November 12, 2024. Accessed November 19, 2024. https://www.globenewswire.com/news-release/2024/11/12/2978893/0/en/Opthea-s-Wet-AMD-Program-Featured-at-Ophthalmology-Events.html
2. The Ophthalmology Innovation Summit. Accessed November 19, 2024. https://ois.net/ois-xiv/